Abstract Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity
By engaging these pathways simultaneously, Retatrutide allows researchers to investigate how coordinated receptor activation impacts glucose metabolism, lipid utilization, appetite regulation, and overall energy balance
Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes mellitus patients with obesity: a retrospective analysis study
These medications require a prescription and professional supervision, as potential side effects might include nausea, diarrhea, constipation, or abdominal discomfort
A study showed that 12-week treatment with cinnamon (500 mg/day) decreased the percentage of fat mass and increased lean mass, improving overall body composition
Tirzepatide (sold as Zepbound for weight loss, Mounjaro for diabetes) produces the most weight loss of any approved drug: about 22.5%